Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration
Subcutaneous meropenem appears to be well tolerated and has a favourable pharmacokinetic profile. Either 1.5 g twice daily or 3 g as a 24 h subcutaneous infusion could be considered for future evaluation.
Authors
- Laurens Manning (ORCID: https://orcid.org/0000-0003-4334-5351)
- Fionnuala Murray (ORCID: https://orcid.org/0000-0003-1653-1351)
- Okhee Yoo (ORCID: https://orcid.org/0000-0001-7285-1953)
- Matthew Rawlins (ORCID: https://orcid.org/0000-0002-6525-1084)
- Sam Salman (ORCID: https://orcid.org/0000-0002-8276-6784)
- Jason A. Roberts (ORCID: https://orcid.org/0000-0001-6218-435X)
- Steven C. Wallis (ORCID: https://orcid.org/0000-0002-2392-9854)
- Edward Raby (ORCID: https://orcid.org/0000-0003-1671-6188)
- Samuel Brophy-Williams
Institutions
- The University of Queensland (AU)
- The Kids Research Institute Australia (AU)
- The University of Western Australia (AU)
- Université de Montpellier (FR)
- Royal Brisbane and Women's Hospital (AU)
- Harry Perkins Institute of Medical Research (AU)
- Fiona Stanley Hospital (AU)
- Fremantle Hospital (AU)
- Metro South Health (AU)
- Infectious Diseases Institute (UG)
- Fiona Stanley Fremantle Hospitals Group
- Université de Nîmes (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1093/jac/dkae398
- Citations
- 8
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 3.58
Funders
- Stan Perron Charitable Foundation